DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies., European Research Council (CoG-2014-646903, PoC-2018-811220)
Spanish Ministry of Science and Innovation (PID2019-105623RB-I00, SAF2016-75656-P, RTC-2017-5944-1, SAF-2019-108160-R, SAF2017-89437-P, PID2020-117323RB-100, PDC2021-121711-100)
Carlos III Health Institute (PI20/01030, PI20/00822, PI16/00357, PI19/00132, PICI14/122, PI13/676, PIE13/33, PI18/775, DTS20/00089)
CatSalut, Fundació La Caixa (CP042702)
Spanish Association Against Cancer (AECC CICPF18030TORI, AECC 19084)
CRIS Cancer Foundation (FCRIS-IFI-2018, FCRIS-IFI-2020)
Spanish Ministry of Science and Innovation under a Ramon y Cajal grant (RYC2018-024442-I)
Comunidad Autónoma de Madrid (PEJD-2018- PRE/BMD-8314)
ISCIII (CM20/00004)
Spanish Ministry of Science and Innovation (PRE2018-083445)
Portuguese Foundation for Science and Technology (SFRH/BD/136574/2018)
Project:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-105623RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-117323RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PDC2021-121711-I00
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-01030
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-00822
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI16-00357
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19-00132
,
ISCIII DTS20-00089
View at: http://hdl.handle.net/10261/370375